Page last updated: 2024-11-11

manumycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

manumycin: an NSAID; RN given for (1S-(1alpha,3(2E,4E,6S*),5alpha,5(1E,3E,5E),6alpha))-isomer; a farnesyl protein transferase inhibitor; from Streptomyces parvulus; MF C31-H38-N2-O7; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

manumycin A : A polyketide with formula C31H38N2O7 initially isolated from Streptomyces parvulus as a result of a random screening program for farnesyl transferase (FTase) inhibitors. It is a natural product that exhibits anticancer and antibiotic properties. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6438330
CHEBI ID29623
SCHEMBL ID12519093
MeSH IDM0153805

Synonyms (32)

Synonym
nsc-622141
BSPBIO_001231
SMP2_000130
QTL1_000054
52665-74-4
manumycin
manumycin a
NCGC00163464-01
2,4-decadienamide, n-(5-hydroxy-5-(7-((2-hydroxy-5-oxo-1-cyclopenten-1-yl)amino)-7-oxo-1,3,5-heptatrienyl)-2-oxo-7-oxabicyclo(4.1.0)hept-3-en-3-yl)-2,4,6-trimethyl-
ucfi-c
NCGC00163464-02
HMS1990M13
chebi:29623 ,
HMS1792M13
AC1O5PHE ,
(2e,4e,6r)-n-[(1s,5s,6r)-5-hydroxy-5-[(1e,3e,5e)-7-[(2-hydroxy-5-oxocyclopenten-1-yl)amino]-7-oxohepta-1,3,5-trienyl]-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienamide
nsc 622141
oiq298x4xd ,
unii-oiq298x4xd
2,4-decadienamide, n-(5-hydroxy-5-(7-((2-hydroxy-5-oxo-1- cyclopenten-1-yl)amino)-7-oxo-1,3,5-heptatrienyl)-2-oxo-7- oxabicyclo(4.1.0)hept-3-en-3-yl)-2,4,6-trimethyl-
(-)-manumycin a
2,4-decadienamide, n-((1s,5s,6r)-5-hydroxy-5-((1e,3e,5e)-7-((2-hydroxy-5-oxo-1-cyclopenten-1-yl)amino)-7-oxo-1,3,5-heptatrien-1-yl)-2-oxo-7-oxabicyclo(4.1.0)hept-3-en-3-yl)-2,4,6-trimethyl-, (2e,4e,6r)-
ucf-1c
SCHEMBL12519093
(2e,4e,6r)-n-[(1s,5s,6r)-5-hydroxy-5-[(1e,3e,5e)-7-[(2-hydroxy-5-oxo-cyclopenten-1-yl)amino]-7-oxo-hepta-1,3,5-trienyl]-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyl-deca-2,4-dienamide
HMS3403M13
LMFA08020185
Q27110184
CS-0100050
HY-N6796
DTXSID401025744
AKOS040742100

Research Excerpts

Overview

Manumycin A (MA) is a well-tolerated natural antibiotic showing pleiotropic anticancer effects in various preclinical in vitro and in vivo models. Manu A is a natural antibiotic produced by new Streptomyces strain, exhibiting antitumor and antic cancer effects.

ExcerptReferenceRelevance
"Manumycin A (MA) is a well-tolerated natural antibiotic showing pleiotropic anticancer effects in various preclinical in vitro and in vivo models. "( Inhibition of the Heat Shock Protein A (HSPA) Family Potentiates the Anticancer Effects of Manumycin A.
Gogler-Pigłowska, A; Hasterok, S; Scieglinska, D; Sojka, DR; Toma-Jonik, A; Vydra, N; Wieczorek, A, 2021
)
2.28
"Manumycin-A (Man-A) is a natural, well-tolerated microbial metabolite and a potent experimental tumoricide."( The natural tumorcide Manumycin-A targets protein phosphatase 1α and reduces hydrogen peroxide to induce lymphoma apoptosis.
Carey, GB; Daino, H; Roy, SK, 2015
)
1.45
"Manumycin A (Manu A) is a natural antibiotic produced by new Streptomyces strain, exhibiting antitumor and anticancer effects. "( Manumycin A from a new Streptomyces strain induces endoplasmic reticulum stress-mediated cell death through specificity protein 1 signaling in human oral squamous cell carcinoma.
Chae, JI; Cho, JH; Cho, JJ; Cho, SS; Cho, YS; Jeon, YJ; Kim, KH; Oh, HN; Shim, JH; Yoon, DY; Yoon, G, 2015
)
3.3
"Manumycin A (Manu A) is a natural product isolated from Streptomyces parvulus and has been reported to have anti-carcinogenic and anti-biotic properties. "( Manumycin A induces apoptosis in malignant pleural mesothelioma through regulation of Sp1 and activation of the mitochondria-related apoptotic pathway.
Chae, JI; Cho, JH; Cho, SS; Cho, YS; Kim, KH; Lee, HJ; Lee, MH; Lee, RH; Liu, K; Oh, H; Shim, JH; Yoon, G, 2016
)
3.32
"Manumycin A is a natural antibiotic isolated from Streptomyces parvulus with broad range of biological activities including antineoplastic activity in several in vitro and in vivo cancer models. "( Antitumor effect of the combination of manumycin A and Immodin is associated with antiplatelet activity and increased granulocyte tumor infiltration in a 4T1 breast tumor model.
Bojková, B; Demečková, V; Fedoročko, P; Gancarčíková, S; Hrčková, G; Jendželovský, R; Kassayová, M; Mudroňová, D; Sačková, V; Solár, P, 2017
)
2.17
"Manumycin A is a natural antibiotic produced by Streptomyces parvulus that has antineoplastic activity against a variety of human cancers in nude mouse models. "( High-performance liquid chromatographic assay validation of Manumycin A in mouse plasma.
Gonzales, J; Jim Yeung, SC; Smith, JA, 2002
)
2
"Manumycin A is a potent and selective farnesyltransferase inhibitor with antitumor activity."( Binding of manumycin A inhibits IkappaB kinase beta activity.
Bernier, M; Decabo, R; He, HJ; Kole, S; Kwon, YK; Maciuk, A; Pandey, SK; Zhao, RJ; Zhu, TN, 2006
)
1.45
"Manumycin-A (Man-A) is a farnesyltransferase inhibitor (FTI), which was originally identified as an effective tumoricide against several cancers, especially ones harboring constitutively active Ras. "( Reactive oxygen species-dependent destruction of MEK and Akt in Manumycin stimulated death of lymphoid tumor and myeloma cell lines.
Carey, GB; Daino, H; Sears, KT, 2008
)
2.03

Actions

Manumycin could inhibit the growth of human hepatocellular carcinoma HepG2 xenografts. Its inhibitory effect on pan-Ras of cell membrane was much stronger.

ExcerptReferenceRelevance
"Manumycin could inhibit both pan-Ras and N-Ras in human hepatoma HepG2 cells, but its inhibitory effect on pan-Ras of cell membrane was much stronger."( [Correlation between inhibitory effect of Manumycin on human hepatoma cancer cell HepG2 and Ras signal transduction pathway].
Fu, LW; Liang, YJ; Liao, DF; Liu, ZC; Pan, QC; Yang, XP; Zhou, JM, 2002
)
1.3
"Manumycin could inhibit the growth of human hepatocellular carcinoma HepG2 xenografts in nude mice. "( [Antitumor and anti-angiogenic effects of manumycin on human hepatocellular carcinoma HepG2 xenografts in nude mice].
Fu, LW; Liang, YJ; Liu, ZC; Pan, QC; Yang, XP; Zhou, JM; Zhu, XF, 2005
)
2.04

Treatment

Manumycin A treatment for 22 weeks decreased Ras activity, and reduced fatty streak lesion size at the aortic sinus to 43% of that in vehicle-treated apoE-deficient mice (P<0.05) Plasma total cholesterol was unaltered.

ExcerptReferenceRelevance
"Manumycin A treatment for 22 weeks decreased Ras activity, and reduced fatty streak lesion size at the aortic sinus to 43% of that in vehicle-treated apoE-deficient mice (P<0.05), while plasma total cholesterol was unaltered. "( Farnesyltransferase inhibitor, manumycin a, prevents atherosclerosis development and reduces oxidative stress in apolipoprotein E-deficient mice.
Kaneki, M; Sugita, H; Sugita, M, 2007
)
2.07
"Cell treatment with manumycin blocked insulin's ability to suppress pro-apoptotic caspase-3 activity which led to time-dependent proteolytic cleavage of two nuclear target proteins."( Akt-dependent antiapoptotic action of insulin is sensitive to farnesyltransferase inhibitor.
Bernier, M; Kole, S; Maksimova, E; Pandey, SK; Park, D, 2000
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
" This study was to investigate apoptosis induced by manumycin combined with methoxyamine in myeloid leukemia cell line U937, and to explore the role of mitochondrial apoptotic pathway in apoptosis induction of the two drugs."( [Effects of manumycin combined with methoxyamine on apoptosis in myeloid leukemia U937 cells].
Guo, KY; Lu, XX; Niu, XQ; She, MR, 2008
)
0.98
" Moreover, the drug combination resulted in enhanced apoptosis in U937 cells."( [Effects of manumycin combined with methoxyamine on apoptosis in myeloid leukemia U937 cells].
Guo, KY; Lu, XX; Niu, XQ; She, MR, 2008
)
0.72

Dosage Studied

In vitro, all compounds demonstrated growth inhibition at a dose-response manner. However, manumycin, gliotoxin, and DHEA demonstrated an initial increase in growth rate at lower doses.

ExcerptRelevanceReference
" In vitro, all compounds demonstrated growth inhibition at a dose-response manner; however, manumycin, gliotoxin, and DHEA demonstrated an initial increase in growth rate at lower doses."( Chemopreventive efficacy of promising farnesyltransferase inhibitors.
Crist, KA; Hara, M; Lantry, LE; Lubet, RA; Wang, Y; You, M; Zeeck, A; Zhang, Z, 2000
)
0.53
"The dose-response curve of manumycin was shifted to the left after addition of methoxyamine."( [Effects of manumycin combined with methoxyamine on apoptosis in myeloid leukemia U937 cells].
Guo, KY; Lu, XX; Niu, XQ; She, MR, 2008
)
1.02
" To better understand the contributions of different signaling pathways, the expression and role of Ras activation was evaluated after oral dosing of mice with APAP (400-500 mg/kg)."( Farnesyltransferase inhibitors reduce Ras activation and ameliorate acetaminophen-induced liver injury in mice.
Nandi, D; Saha, B, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (8)

RoleDescription
EC 1.8.1.9 (thioredoxin reductase) inhibitorAn EC 1.8.1.* (oxidoreductase acting on sulfur group of donors, NAD+ or NADP+ as acceptor) inhibitor that interferes with the action of thioredoxin reductase (EC 1.8.1.9).
EC 2.5.1.58 (protein farnesyltransferase) inhibitorAn EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of protein farnesyltransferase (EC 2.5.1.58), one of the three enzymes in the prenyltransferase group.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
antiatherosclerotic agentA cardiovascular drug that prevents atherosclerosis (a disease in which the inside of an artery narrows due to the build up of plaque). Compare with antiatherogenic agent.
marine metaboliteAny metabolite produced during a metabolic reaction in marine macro- and microorganisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
polyketideNatural and synthetic compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations, etc. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides.
enamideAn alpha,beta-unsaturated carboxylic acid amide of general formula R(1)R(2)C=CR(3)-C(=O)NR(4)R(5) in which the amide C=O function is conjugated to a C=C double bond at the alpha,beta position.
epoxideAny cyclic ether in which the oxygen atom forms part of a 3-membered ring.
organic heterobicyclic compound
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
tertiary alcoholA tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency22.38720.003245.467312,589.2998AID2517
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency35.48130.125919.1169125.8920AID2549
Chain A, Ferritin light chainEquus caballus (horse)Potency31.62285.623417.292931.6228AID485281
phosphopantetheinyl transferaseBacillus subtilisPotency8.91250.141337.9142100.0000AID1490
Bloom syndrome protein isoform 1Homo sapiens (human)Potency25.11890.540617.639296.1227AID2528
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency2.23870.354828.065989.1251AID504847
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency0.85280.00798.23321,122.0200AID2546; AID2551
DNA polymerase kappa isoform 1Homo sapiens (human)Potency26.67950.031622.3146100.0000AID588579
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thioredoxin reductase 1, cytoplasmicRattus norvegicus (Norway rat)IC50 (µMol)0.81000.27201.82606.0000AID1410367; AID1410368; AID1410369
GTPase KRasHomo sapiens (human)IC50 (µMol)3.58000.00841.13345.8800AID1893890
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)IC50 (µMol)11.90000.00050.471610.0000AID72823
Protein farnesyltransferase subunit betaHomo sapiens (human)IC50 (µMol)11.90000.00050.21772.5000AID72823
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Processvia Protein(s)Taxonomy
MAPK cascadeGTPase KRasHomo sapiens (human)
positive regulation of protein phosphorylationGTPase KRasHomo sapiens (human)
visual learningGTPase KRasHomo sapiens (human)
gene expressionGTPase KRasHomo sapiens (human)
positive regulation of gene expressionGTPase KRasHomo sapiens (human)
glial cell proliferationGTPase KRasHomo sapiens (human)
Rac protein signal transductionGTPase KRasHomo sapiens (human)
forebrain astrocyte developmentGTPase KRasHomo sapiens (human)
actin cytoskeleton organizationGTPase KRasHomo sapiens (human)
negative regulation of epithelial cell differentiationGTPase KRasHomo sapiens (human)
regulation of synaptic transmission, GABAergicGTPase KRasHomo sapiens (human)
positive regulation of Rac protein signal transductionGTPase KRasHomo sapiens (human)
skeletal muscle cell differentiationGTPase KRasHomo sapiens (human)
negative regulation of neuron apoptotic processGTPase KRasHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityGTPase KRasHomo sapiens (human)
homeostasis of number of cells within a tissueGTPase KRasHomo sapiens (human)
striated muscle cell differentiationGTPase KRasHomo sapiens (human)
neuron apoptotic processGTPase KRasHomo sapiens (human)
positive regulation of glial cell proliferationGTPase KRasHomo sapiens (human)
epithelial tube branching involved in lung morphogenesisGTPase KRasHomo sapiens (human)
type I pneumocyte differentiationGTPase KRasHomo sapiens (human)
Ras protein signal transductionGTPase KRasHomo sapiens (human)
transforming growth factor beta receptor signaling pathwayProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein geranylgeranylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of Rac protein signal transductionProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
skeletal muscle acetylcholine-gated channel clusteringProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of tubulin deacetylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of deacetylase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of skeletal muscle acetylcholine-gated channel clusteringProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
lipid metabolic processProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesylationProtein farnesyltransferase subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
GTPase activityGTPase KRasHomo sapiens (human)
G protein activityGTPase KRasHomo sapiens (human)
protein bindingGTPase KRasHomo sapiens (human)
protein-membrane adaptor activityGTPase KRasHomo sapiens (human)
protein-containing complex bindingGTPase KRasHomo sapiens (human)
GDP bindingGTPase KRasHomo sapiens (human)
GTP bindingGTPase KRasHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
Rab geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
microtubule bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
receptor tyrosine kinase bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
alpha-tubulin bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
molecular adaptor activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase subunit betaHomo sapiens (human)
protein bindingProtein farnesyltransferase subunit betaHomo sapiens (human)
zinc ion bindingProtein farnesyltransferase subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
Golgi membraneGTPase KRasHomo sapiens (human)
cytoplasmGTPase KRasHomo sapiens (human)
mitochondrial outer membraneGTPase KRasHomo sapiens (human)
endoplasmic reticulum membraneGTPase KRasHomo sapiens (human)
cytosolGTPase KRasHomo sapiens (human)
plasma membraneGTPase KRasHomo sapiens (human)
focal adhesionGTPase KRasHomo sapiens (human)
cytoplasmic side of plasma membraneGTPase KRasHomo sapiens (human)
membraneGTPase KRasHomo sapiens (human)
plasma membraneGTPase KRasHomo sapiens (human)
cytosolProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
plasma membraneProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
microtubule associated complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
cytoplasmProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
cytosolProtein farnesyltransferase subunit betaHomo sapiens (human)
microtubule associated complexProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesyltransferase complexProtein farnesyltransferase subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1410369Inhibition of NADPH-reduced recombinant rat TrxR1 expressed in Escherichia coli harboring gor mutant assessed as suppression of DTNB reduction incubated for 1 hr in presence of DTNB measured every 5 mins for 1 hr2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1).
AID1410372Inhibition of oxidized recombinant rat TrxR1 expressed in Escherichia coli harboring gor mutant assessed as suppression of DTNB reduction at 2 uM pretreated for 30 mins followed by NADPH addition for 30 mins and subsequent DTNB addition measured every 5 m2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1).
AID1893890Antiproliferative activity against human COLO 320DM cells harboring wild type KRAS assessed as reduction in cell viability incubated for 24 hrs in presence of MVA2021European journal of medicinal chemistry, Feb-05, Volume: 211Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
AID377439Antimicrobial activity against Staphylococcus aureus at 10 ug/plate2005Journal of natural products, Mar, Volume: 68, Issue:3
Chinikomycins A and B: isolation, structure elucidation, and biological activity of novel antibiotics from a marine Streptomyces sp. isolate M045.
AID1410377Inhibition of NADPH-reduced TrxR1 in human GM02152 cells assessed as suppression of insulin reduction by measuring enzyme rate using Trx as substrate pretreated for 30 mins followed by Trx addition for 30 mins and subsequent eosin-labelled bovine insulin 2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1).
AID1410375Induction of recombinant rat TrxR1 NADPH oxidase activity expressed in Escherichia coli harboring gor mutant assessed as increase in NADPH consumption at 62.5 uM measured after 30 mins relative to control2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1).
AID377444Antimicrobial activity against Mucor miehei at 10 ug/plate2005Journal of natural products, Mar, Volume: 68, Issue:3
Chinikomycins A and B: isolation, structure elucidation, and biological activity of novel antibiotics from a marine Streptomyces sp. isolate M045.
AID1410376Induction of recombinant rat TrxR1 NADPH oxidase activity expressed in Escherichia coli harboring gor mutant assessed as superoxide generation by measuring cytochrome C reduction at 62.5 uM measured in presence of SOD2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1).
AID377441Antimicrobial activity against Chlorella vulgaris at 10 ug/plate2005Journal of natural products, Mar, Volume: 68, Issue:3
Chinikomycins A and B: isolation, structure elucidation, and biological activity of novel antibiotics from a marine Streptomyces sp. isolate M045.
AID72823Inhibition of [3H]farnesyl pyrophosphate binding to human farnesyltransferase2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
A novel metal-chelating inhibitor of protein farnesyltransferase.
AID1410373Inhibition of NADPH-reduced recombinant rat TrxR1 expressed in Escherichia coli harboring gor mutant assessed as suppression of insulin reduction at 20 uM using Trx as substrate pretreated for 30 mins followed by Trx addition for 30 mins and subsequent eo2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1).
AID1410366Inhibition of NADPH-reduced TrxR1 in human GM02152 cells assessed as suppression of insulin reduction by measuring enzyme rate using Trx as substrate pretreated for 30 mins followed by Trx addition for 30 mins and subsequent eosin-labelled bovine insulin 2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1).
AID377445Antimicrobial activity against Candida albicans at 10 ug/plate2005Journal of natural products, Mar, Volume: 68, Issue:3
Chinikomycins A and B: isolation, structure elucidation, and biological activity of novel antibiotics from a marine Streptomyces sp. isolate M045.
AID1410379Inhibition of NADPH-reduced recombinant rat TrxR1 expressed in Escherichia coli harboring gor mutant assessed as suppression of DTNB reduction at 5 uM incubated for 1 hr in presence of DTNB measured every 5 mins for 1 hr2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1).
AID377442Antimicrobial activity against Chlorella sorokiniana at 10 ug/plate2005Journal of natural products, Mar, Volume: 68, Issue:3
Chinikomycins A and B: isolation, structure elucidation, and biological activity of novel antibiotics from a marine Streptomyces sp. isolate M045.
AID1410371Irreversible inhibition of NADPH-reduced recombinant rat TrxR1 expressed in Escherichia coli harboring gor mutant assessed as suppression of DTNB reduction at 2 uM pretreated for 1 hr followed by NADPH addition for 30 mins and subsequent DTNB addition mea2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1).
AID377437Antimicrobial activity against Bacillus subtilis at 10 ug/plate2005Journal of natural products, Mar, Volume: 68, Issue:3
Chinikomycins A and B: isolation, structure elucidation, and biological activity of novel antibiotics from a marine Streptomyces sp. isolate M045.
AID1410367Inhibition of NADPH-reduced recombinant rat TrxR1 expressed in Escherichia coli harboring gor mutant assessed as suppression of insulin reduction using Trx as substrate pretreated for 30 mins followed by Trx addition for 30 mins and subsequent eosin-label2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1).
AID377440Antimicrobial activity against Escherichia coli at 10 ug/plate2005Journal of natural products, Mar, Volume: 68, Issue:3
Chinikomycins A and B: isolation, structure elucidation, and biological activity of novel antibiotics from a marine Streptomyces sp. isolate M045.
AID1410374Drug metabolism assessed as selenocysteine reactivity at 20 uM incubated for 1 hr measured every 5 mins for 1 hr by sel-green probe based fluorescence assay2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1).
AID1410368Inhibition of NADPH-reduced recombinant rat TrxR1 expressed in Escherichia coli harboring gor mutant assessed as suppression of DTNB reduction pretreated for 1 hr followed by DTNB addition measured every 5 mins for 1 hr2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1).
AID1410370Time-dependent inhibition of NADPH-reduced recombinant rat TrxR1 expressed in Escherichia coli harboring gor mutant assessed as suppression of DTNB reduction at 1 uM measured every 5 mins for 1 hr2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1).
AID377443Antimicrobial activity against Scenedesmus subspicatus at 10 ug/plate2005Journal of natural products, Mar, Volume: 68, Issue:3
Chinikomycins A and B: isolation, structure elucidation, and biological activity of novel antibiotics from a marine Streptomyces sp. isolate M045.
AID377438Antimicrobial activity against Streptomyces viridochromogenes Tu 57 at 10 ug/plate2005Journal of natural products, Mar, Volume: 68, Issue:3
Chinikomycins A and B: isolation, structure elucidation, and biological activity of novel antibiotics from a marine Streptomyces sp. isolate M045.
AID1410378Inhibition of NADPH-reduced recombinant rat TrxR1 expressed in Escherichia coli harboring gor mutant assessed as suppression of DTNB reduction at 5 uM pretreated for 1 hr followed by DTNB addition measured every 5 mins for 1 hr2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1).
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (156)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (3.21)18.7374
1990's23 (14.74)18.2507
2000's76 (48.72)29.6817
2010's43 (27.56)24.3611
2020's9 (5.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.15 (24.57)
Research Supply Index5.08 (2.92)
Research Growth Index5.25 (4.65)
Search Engine Demand Index38.04 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews7 (4.40%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other152 (95.60%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]